Please assess the completion status of the following clinical trial:

Trial Title: China Stroke Primary Prevention Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* BP≥140/90 mmHg in both of the two screening visits or currently under anti-hypertension treatment~* 45 - 75 years old~* Successful determination of MTHFR C677T genotype~* For pre-menopausal women, agreed to use contraceptives during the trial~* Signed the written informed consent~Exclusion Criteria:~* Having a history of stroke~* Having a history of myocardial infarction~* Having a history of physician diagnosed heart failure~* Post- coronary revascularization~* Severe somatic disease such as cancer~* Secondary hypertension~* Congenital or acquired organic heart diseases~* Contraindicated to angiotensin-converting enzyme inhibitor(ACEI)~* History of ACEI adverse effects~* Currently long-term use of folic acid or vitamin B12 or vitamin B6~* Pregnant or child breastfeeding women~* Severe mental disorders~* Lab tests indicating abnormal liver or kidney function~* Unwilling to participate the trial, unwilling to change the current antihypertensive treatment

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Enalapril/folic acid (Type: EXPERIMENTAL): A fixed combination drug is given. The dose is fixed in enalapril 10 mg / folic acid 0.8 mg per day.
- Enalapril (Type: ACTIVE_COMPARATOR): Enalapril maleate 10 mg per day is given

Based on this trial design, predict the completion outcome and termination type (if applicable).